MD, PhD @unito 🌺 Ospedale Molinette, Torino
Torino, Piemonte
Joined May 2022
- Tweets48
- Following110
- Followers97
- Likes167
Anna Amela Valsecchi retweeted
How are drug–drug interactions managed in #ProstateCancer?
Our international survey in collabs with ONCOassist reveals gaps in DDI management, highlighting the need for reliable tools & multidisciplinary collaboration.
doi.org/10.1093/oncolo/oyag3…
Anna Amela Valsecchi retweeted
💥Recognising #FinantialToxicity as a prognostic factor and integrating targeted support services, educational strategies and systemic reforms could substantially improve patient outcomes, #QoL, treatment adherence and equity in #CancerCare delivery.
Learn more at the link
🔓journals.sagepub.com/share/N…
@MassimoDiMaio75 @fperrone62 @AAValsecchi
Anna Amela Valsecchi retweeted
Even within the same country (Italy), use of off-label cancer drugs is subject to significant inter-hospital variability.
This leads to potential disparities in patients' access to care.
Have a look at the project by @AIOMtweet, just published on @TumoriJ:
journals.sagepub.com/eprint/…
Anna Amela Valsecchi retweeted
Bone Health and Body Composition as Predictive and Prognostic Markers in Metastatic Castration-resistant Prostate Cancer: A Meet-URO Narrative Review.
Doi: doi.org/10.1016/j.clgc.2025.…
@AAValsecchi #meeturo #clinicalgenitourinarycancer
Anna Amela Valsecchi retweeted
Standing ovation for this trial at #ASCO25 .
Practice changing.
The problem could be the adherence to physical exercise. Accrual in the trial was very slow, because many patients refused randomization to exercise, I suppose.
Education is crucial.
Presented at #ASCO25:
A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results: nej.md/4mh5RPL
@ASCO
Anna Amela Valsecchi retweeted
Check out our open access review on the association between #QoL measures and survival endpoints in #cancer clinical trials and in clinical decision making.
Kudos to @AAValsecchi
link.springer.com/article/10…
Anna Amela Valsecchi retweeted
Grateful to the oncology residents at @unito for the warm welcome during their Didactic Week, fantastic initiative by Silvia Novello to learn, network & grow together.
Thanks to @LulieZumstein, @AAValsecchi & @O_Cantale for the flawless organization!
Loved their curiosity!
Anna Amela Valsecchi retweeted
Bone Health and Body Composition Consensus results: look inside!
esmoopen.com/article/S2059-7…
Thanks to all!
@AIOMtweet @MassimoDiMaio75 @g_procopio_ @AAValsecchi @AlfredoBerruti
Anna Amela Valsecchi retweeted
I registri AIFA: non solo burocrazia ma fonte di evidenza? tinyurl.com/24w5bz9p
Anna Amela Valsecchi retweeted
Side-effect of hormonal therapy💊
Updated picture of #management of bone health🦴 in pts with #BreastCancer undergoing adjuvant hormonal therapy and in pts with hormone sensitive #prostatecancer
@AIOMtweet survey📝
🔗journals.sagepub.com/share/Q…
Anna Amela Valsecchi retweeted
Have a look at our updated systematic review and meta-analysis of the frequency of germline and somatic BRCA1 and BRCA2 mutations in patients with prostate cancer
Good job @AAValsecchi !
mdpi.com/2262864 #mdpicancers via @Cancers_MDPI
Anna Amela Valsecchi retweeted
#CaseReport aiming to emphasize clinical value of a chronic chemotherapy treatment also in heavily pretreated and luminal-like metastatic #breastcancer ➡️#eribulin a good choice to consider💊
🔗journals.sagepub.com/share/B…
@AAValsecchi @JessicaPaparo #bcsm #MedTwitter
Anna Amela Valsecchi retweeted
For me one of the greatest satisfactions of this 2022 that is going to end...
Thanks @myESMO
ESMO Clinical Practice Guidelines: role of patient-reported outcome measures in continuum of #cancercare. Evidence, clinical scenarios, instruments, implementation, applicability & limitations.
ow.ly/75gn50Maeqq
@MassimoDiMaio75 @Lorrwarr @sundap15 @Annals_Oncology
Anna Amela Valsecchi retweeted
🎯📣 A true pleasure to present our meta-analysis evaluating the role of MEKis in #LGSOC!!
It’s a honour to collaborate with these experts 🙏🏻!!!
@MassimoDiMaio75 @annafagottimd @PignataSandro @AAValsecchi @gaia_giannone @Barto_Med
Article in press: 👉🏻 cancertreatmentreviews.com/a…